Japanese Chugai Revises First Quarter Profit Outlook
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Chugai Pharmaceutical said April 22 its net income in the first quarter dropped by roughly 50 percent compared to the same period last year due to weak sales of its influenza vaccine Tamiflu (oseltamivir). However, the Tokyo-based company revised and lifted its profit outlook until the end of the year in part due to lower than expected drug repricing efforts by the government
You may also be interested in...
Chugai Applies For Expiration Date Extension On Stockpiled Tamiflu
The Japanese importer of the flu drug Tamiflu, Chugai Pharma, has applied to the Ministry of Health, Labor and Welfare to extend the expiration date of the product, which is stockpiled by Japanese national and local governments, from the current five years to seven years. To prepare for a possible flu pandemic, the government and local authorities have invested ¥54.4 billion to stockpile Tamiflu. Under the current expiration date, some of that stockpile will expire in two years and have to be disposed of. (Click here for more-Japanese language)
Japan To Cut Drug Prices in April
TOKYO - In the beginning of March, Japan's Ministry of Health, Labour and Welfare plans to release a full list of drugs that will be repriced starting in April. The average price cut is expected to be roughly 5.2 percent and includes top-selling prescription drugs
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).